Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TransCon CNP in children with achondroplasia (China, Phase 2)
CTR20211558Phase 2Completed
- Sponsor
- Ascendis Pharma
- Start
- Jul 2021
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of navepegritide in achondroplasia (ACH), sponsored by Ascendis Pharma. Started Jul 2021; status: completed.
02
Drugs
navepegritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on CTR20211558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211558.